Saturday - May 17, 2025

LOGIN  |  REGISTER
Recursion
Chimerix

UnitedHealth Announces Earnings Release Date

September 13, 2023 | Last Trade: US$291.65 17.30 6.31

MINNETONKA, Minn. / Sep 13, 2023 / Business Wire / UnitedHealth Group (NYSE: UNH) will release its third quarter 2023 financial results on Friday, October 13, 2023, before the market opens, and will host a teleconference at 8:45 a.m. ET to discuss the results with analysts and investors. This call will be webcast on the Investor Relations page of the company’s web site (www.unitedhealthgroup.com). The replay will be available through October 27 on the web site.

About UnitedHealth Group

UnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at www.unitedhealthgroup.com and follow UnitedHealth Group on LinkedIn.

Stock Quote

Last Trade: US$291.65
Daily Change: 17.30 6.31
Daily Volume: 69,784,397
Market Cap: US$268.400B

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page